Carna Biosciences Overview

  • Founded
  • 2003


  • Status
  • Public

  • Employees
  • 73


  • Stock Symbol
  • 4572

Stock Symbol

  • Investments
  • 1

  • Share Price
  • $4.95
  • (As of Wednesday Closing)

Carna Biosciences General Information


Carna Biosciences, Inc is a Japanese company engaged in drug discovery support business and drug discovery and development business. The company identifies and develops medicines primarily for the treatment of cancer and inflammatory diseases using own innovative kinase drug discovery platform, QuickScout.

Contact Information

Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Other Industries
Drug Discovery
Stock Exchange
Primary Office
  • BMA 3F 1-5-5 Minatojima-Minamimachi
  • Chuo-ku
  • Kobe, 650-0047
  • Japan
+81 000-000-0000

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Carna Biosciences Stock Performance

(As of Wednesday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$4.95 $5.05 $3.36 - $7.45 $89.9M 17.1M 1.22M -$0.92

Carna Biosciences Financials Summary

In Thousands,
TTM 30-Jun-2023 FY 2022 31-Dec-2022 FY 2021 31-Dec-2021 FY 2020 31-Dec-2020
EV 55,588 29,922 95,661 105,510
Revenue 7,632 10,552 18,372 10,614
EBITDA (13,131) (9,774) (4,640) (10,140)
Net Income (13,664) (10,269) (4,867) (10,405)
Total Assets 31,528 32,539 47,211 46,885
Total Debt 1,564 2,291 4,692 4,167
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Carna Biosciences Valuation & Funding

Deal Type Date Amount Valuation/
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Carna Biosciences‘s full profile, request access.

Request a free trial

Carna Biosciences Patents

Carna Biosciences Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20230097964-A1 Novel 1,2-diaminobenzimidazole derivative Pending 21-Jul-2021 0000000000
CA-3173510-A1 Novel benzimidazole derivative Pending 25-Mar-2020 0000000000
EP-4129406-A1 Novel benzimidazole derivative Pending 25-Mar-2020 0000000000
EP-4101468-A1 Anticancer agent composition Pending 05-Feb-2020 000000000
US-20230100235-A1 Anticancer agent composition Pending 05-Feb-2020 A61K45/06
To view Carna Biosciences’s complete patent history, request access »

Carna Biosciences Executive Team (2)

Name Title Board Seat Contact Info
Kohichiro Yoshino Ph.D Founder, President, Chief Executive Officer & Representative Director
You’re viewing 1 of 2 executive team members. Get the full list »

Carna Biosciences Signals

Growth Rate

0.80% Weekly
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers


Similarweb Unique Visitors


Majestic Referring Domains


PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Carna Biosciences Acquisitions (1)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
000000 01-Oct-2013 0000000000 00.00 Other Healthcare Services
To view Carna Biosciences’s complete acquisitions history, request access »

Carna Biosciences ESG

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.


Covered Companies







Laboratory Equipment and Services




To view Carna Biosciences’s complete esg history, request access »